These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 17729183)

  • 1. Novel therapies to increase apolipoprotein AI and HDL for the treatment of atherosclerosis.
    Wong NC
    Curr Opin Investig Drugs; 2007 Sep; 8(9):718-28. PubMed ID: 17729183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apolipoprotein AI and high-density lipoprotein have anti-inflammatory effects on adipocytes via cholesterol transporters: ATP-binding cassette A-1, ATP-binding cassette G-1, and scavenger receptor B-1.
    Umemoto T; Han CY; Mitra P; Averill MM; Tang C; Goodspeed L; Omer M; Subramanian S; Wang S; Den Hartigh LJ; Wei H; Kim EJ; Kim J; O'Brien KD; Chait A
    Circ Res; 2013 May; 112(10):1345-54. PubMed ID: 23501697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors controlling nascent high-density lipoprotein particle heterogeneity: ATP-binding cassette transporter A1 activity and cell lipid and apolipoprotein AI availability.
    Lyssenko NN; Nickel M; Tang C; Phillips MC
    FASEB J; 2013 Jul; 27(7):2880-92. PubMed ID: 23543682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacologic elevation of high-density lipoproteins: recent insights on mechanism of action and atherosclerosis protection.
    Meyers CD; Kashyap ML
    Curr Opin Cardiol; 2004 Jul; 19(4):366-73. PubMed ID: 15218398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-density lipoprotein synthesis and metabolism (Review).
    Zhou L; Li C; Gao L; Wang A
    Mol Med Rep; 2015 Sep; 12(3):4015-4021. PubMed ID: 26082200
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacologic augmentation of high-density lipoproteins: mechanisms of currently available and emerging therapies.
    Meyers CD; Kashyap ML
    Curr Opin Cardiol; 2005 Jul; 20(4):307-12. PubMed ID: 15956828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of HDL-modulating interventions for cardiovascular risk reduction using a systems pharmacology approach.
    Gadkar K; Lu J; Sahasranaman S; Davis J; Mazer NA; Ramanujan S
    J Lipid Res; 2016 Jan; 57(1):46-55. PubMed ID: 26522778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dysfunctional HDL as a diagnostic and therapeutic target.
    Smith JD
    Arterioscler Thromb Vasc Biol; 2010 Feb; 30(2):151-5. PubMed ID: 19679832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HDL-targeted therapies: progress, failures and future.
    Kingwell BA; Chapman MJ; Kontush A; Miller NE
    Nat Rev Drug Discov; 2014 Jun; 13(6):445-64. PubMed ID: 24854407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HDL as a treatment target.
    Brown WV; Brewer HB; Rader DJ; Schaefer EJ
    J Clin Lipidol; 2010; 4(1):5-16. PubMed ID: 21122624
    [No Abstract]   [Full Text] [Related]  

  • 11. Recent advances in niacin and lipid metabolism.
    Kamanna VS; Ganji SH; Kashyap ML
    Curr Opin Lipidol; 2013 Jun; 24(3):239-45. PubMed ID: 23619367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-density lipoprotein particles, coronary heart disease, and niacin.
    Asztalos BF
    J Clin Lipidol; 2010; 4(5):405-10. PubMed ID: 21122684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The high-fat high-fructose hamster as an animal model for niacin's biological activities in humans.
    Connolly BA; O'Connell DP; Lamon-Fava S; LeBlanc DF; Kuang YL; Schaefer EJ; Coppage AL; Benedict CR; Kiritsy CP; Bachovchin WW
    Metabolism; 2013 Dec; 62(12):1840-9. PubMed ID: 24035454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Niacin increases HDL by reducing hepatic expression and plasma levels of cholesteryl ester transfer protein in APOE*3Leiden.CETP mice.
    van der Hoorn JW; de Haan W; Berbée JF; Havekes LM; Jukema JW; Rensen PC; Princen HM
    Arterioscler Thromb Vasc Biol; 2008 Nov; 28(11):2016-22. PubMed ID: 18669886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
    Hausenloy DJ; Yellon DM
    Postgrad Med J; 2008 Nov; 84(997):590-8. PubMed ID: 19103817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current Therapies Focused on High-Density Lipoproteins Associated with Cardiovascular Disease.
    Estrada-Luna D; Ortiz-Rodriguez MA; Medina-Briseño L; Carreón-Torres E; Izquierdo-Vega JA; Sharma A; Cancino-Díaz JC; Pérez-Méndez O; Belefant-Miller H; Betanzos-Cabrera G
    Molecules; 2018 Oct; 23(11):. PubMed ID: 30360466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipid efflux by the ATP-binding cassette transporters ABCA1 and ABCG1.
    Cavelier C; Lorenzi I; Rohrer L; von Eckardstein A
    Biochim Biophys Acta; 2006 Jul; 1761(7):655-66. PubMed ID: 16798073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is raising HDL a futile strategy for atheroprotection?
    Joy T; Hegele RA
    Nat Rev Drug Discov; 2008 Feb; 7(2):143-55. PubMed ID: 18239670
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo macrophage-specific RCT and antioxidant and antiinflammatory HDL activity measurements: New tools for predicting HDL atheroprotection.
    Escolà-Gil JC; Rotllan N; Julve J; Blanco-Vaca F
    Atherosclerosis; 2009 Oct; 206(2):321-7. PubMed ID: 19362310
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Statins and metabolism of high density lipoprotein.
    Sviridov D; Nestel P; Watts G
    Cardiovasc Hematol Agents Med Chem; 2007 Jul; 5(3):215-21. PubMed ID: 17630948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.